Androgen Antagonists

"Androgen Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Compounds which inhibit or antagonize the biosynthesis or actions of androgens.

Descriptor ID	D000726
MeSH Number(s)	D06.347.065 D27.505.696.399.450.065
Concept/Terms	Androgen Antagonists Androgen Antagonists Antagonists, Androgen Antiandrogens Anti-Androgen Effect Anti-Androgen Effect Anti Androgen Effect Effect, Anti-Androgen Antiandrogen Effect Effect, Antiandrogen Antiandrogen Effects Effects, Antiandrogen Anti-Androgen Effects Anti Androgen Effects Effects, Anti-Androgen

Below are MeSH descriptors whose meaning is more general than "Androgen Antagonists".

Chemicals and Drugs [D]
Hormones, Hormone Substitutes, and Hormone Antagonists [D06]
Hormone Antagonists [D06.347]
Androgen Antagonists [D06.347.065]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Physiological Effects of Drugs [D27.505.696]
Hormones, Hormone Substitutes, and Hormone Antagonists [D27.505.696.399]
Hormone Antagonists [D27.505.696.399.450]
Androgen Antagonists [D27.505.696.399.450.065]

Below are MeSH descriptors whose meaning is related to "Androgen Antagonists".

Below are MeSH descriptors whose meaning is more specific than "Androgen Antagonists".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Androgen Antagonists" by people in this website by year, and whether "Androgen Antagonists" was a major or minor topic of these publications.

Bar chart showing 201 publications over 29 distinct years, with a maximum of 25 publications in 2023

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	3	1	4
1997	3	2	5
1998	2	0	2
2000	2	0	2
2001	1	0	1
2002	2	1	3
2003	6	5	11
2004	1	1	2
2005	1	1	2
2006	2	0	2
2007	7	2	9
2008	1	3	4
2009	3	1	4
2010	0	4	4
2011	6	2	8
2012	4	2	6
2013	5	4	9
2014	4	5	9
2015	4	1	5
2016	0	2	2
2017	8	4	12
2018	7	0	7
2019	4	2	6
2020	12	4	16
2021	9	6	15
2022	1	9	10
2023	3	22	25
2024	9	6	15
2025	1	0	1

Below are the most recent publications written about "Androgen Antagonists" by people in Profiles.

Prebay ZJ, Fu D, Hochberg AR, Chung PH. Androgen deprivation therapy does not increase rates for reintervention, complication, or infection in primary penile implant or artificial urinary sphincter surgery: a retrospective cohort study from the TriNetX network. Int J Impot Res. 2025 Nov; 37(11):896-901.

View in: PubMed
Shore ND, Morgans AK, Tutrone RF. Testosterone recovery post discontinuation of androgen deprivation for the treatment of advanced prostate cancer. Future Oncol. 2024 Dec; 20(39):3179-3182.

View in: PubMed
Shore ND, Cookson MS, Efstathiou E. The landscape of androgen deprivation therapies for the treatment of advanced prostate cancer. Future Oncol. 2024 Dec; 20(40):3351-3354.

View in: PubMed
Shore N, Brown G, Lowentritt B, O'Donnell L, Wilt W, Burbage S, Khilfeh I, Gaylis F. Evaluating the Importance of Practice-level Factors on Adherence to Prostate Cancer Treatment Guidelines in Urology. Urology. 2025 02; 196:147-154.

View in: PubMed
Marshall CH, Teply BA, Lu J, Oliveira L, Wang H, Mao SS, Kelly WK, Paller CJ, Markowski MC, Denmeade SR, King S, Sullivan R, Davicioni E, Proudfoot JA, Eisenberger MA, Carducci MA, Lotan TL, Antonarakis ES. Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled Trial. JAMA Oncol. 2024 Oct 01; 10(10):1400-1408.

View in: PubMed
Saad F, Vjaters E, Shore N, Olmos D, Xing N, Pereira de Santana Gomes AJ, Cesar de Andrade Mota A, Salman P, Jievaltas M, Ulys A, Jakubovskis M, Kopyltsov E, Han W, Nevalaita L, Testa I, Le Berre MA, Kuss I, Haresh KP. Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial. J Clin Oncol. 2024 12 20; 42(36):4271-4281.

View in: PubMed
Shore N, Hafron J, Saltzstein D, Brown G, Belkoff L, Aggarwal P, Phillips J, Bhaumik A, McGowan T. Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP). J Urol. 2024 11; 212(5):682-691.

View in: PubMed
Hussain M, Fizazi K, Shore ND, Heidegger I, Smith MR, Tombal B, Saad F. Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review. JAMA Oncol. 2024 06 01; 10(6):807-820.

View in: PubMed
Morgans AK, Grossman JP, Paracha N, Ladino D, Tyas E, Rodriguez-Santamaria F, Shore N. Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS. J Manag Care Spec Pharm. 2024 Sep; 30(9):991-1000.

View in: PubMed
Spratt DE, George DJ, Shore ND, Cookson MS, Saltzstein DR, Tutrone R, Bossi A, Brown BA, Lu S, Fallick M, Hanson S, Tombal BF. Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer. JAMA Oncol. 2024 05 01; 10(5):594-602.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement